Article
Clinical Neurology
Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjorn Sperling, Thomas Brevig, Mette Krog Josiassen, Elizabeth Brunner, Loan Honeywell, Lahar Mehta
Summary: The study evaluated the safety and tolerability of the humanized anti-CGRP monoclonal antibody eptinezumab in patients with migraine across five large-scale clinical trials. The results showed a favorable safety and tolerability profile of eptinezumab in adults with migraine, with most adverse events being mild or moderate in severity.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjorn Sperling, Patricia Pozo-Rosich
Summary: The study found that Eptinezumab treatment significantly reduced monthly migraine days and improved treatment response rates in patients with migraine and prior preventive treatment failures. It is effective in different demographic populations and clinical characteristics.
Article
Clinical Neurology
Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjorn Sperling
Summary: This study investigated the safety and efficacy of eptinezumab for patients with migraine and two-to-four previous preventive treatment failures, showing significant migraine preventive effects compared to placebo.
Correction
Clinical Neurology
Lipton
Summary: The study article "Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine: PROMISE-2" by Lipton et al. had minor data errors. A corrected version has been provided, with the original version highlighting the changes. The authors express regret for the errors.
Article
Pharmacology & Pharmacy
Vincent Martin, A. Jim Nagy, Marina Janelidze, Gvantsa Giorgadze, Joe Hirman, Roger Cady, Lahar Mehta, Dawn C. Buse
Summary: In the PROMISE-1 and PROMISE-2 clinical trials, eptinezumab 100 mg and 300 mg demonstrated significant efficacy in reducing monthly migraine days. The impact of baseline demographic and migraine characteristics on treatment efficacy and safety was evaluated, with no clear pattern identified except for the obesity subgroup.
CLINICAL THERAPEUTICS
(2022)
Article
Clinical Neurology
Piero Barbanti, Peter J. Goadsby, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjorn Sperling
Summary: Eptinezumab significantly improves work productivity and daily activity ability in patients with prior preventive treatment failures.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Takao Takeshima, Fumihiko Sakai, Koichi Hirata, Noboru Imai, Yasuhiko Matsumori, Ryuji Yoshida, Cheng Peng, Sunfa Cheng, Daniel D. Mikol
Summary: Erenumab demonstrated favorable efficacy and safety in Japanese patients with episodic or chronic migraine. The study showed a significant reduction in monthly migraine days with erenumab treatment, with a lower incidence of adverse events compared to placebo.
Article
Clinical Neurology
Vincent Martin, Cristina Tassorelli, Anders Ettrup, Joe Hirman, Roger Cady
Summary: This study evaluated the efficacy and safety of eptinezumab in patients aged 50 and above with episodic or chronic migraine. The results showed that eptinezumab significantly reduced the number of migraine days and had a good safety profile.
ACTA NEUROLOGICA SCANDINAVICA
(2022)
Review
Pharmacology & Pharmacy
Yusak Mangara Tua Siahaan, Vinson Hartoyo, Timotius Ivan Hariyanto
Summary: This study analyzed the efficacy and safety of eptinezumab, a CGRP-monoclonal antibody, as a preventive treatment for episodic/chronic migraine. The results showed that eptinezumab was effective in reducing monthly migraine days and improving migraine responder rate, with comparable safety to placebo.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
(2022)
Article
Clinical Neurology
Xinyu Tao, Zeya Yan, Jiahao Meng, Wei Wang, Qiling Dai, Qiufeng Zhou, Zhifeng Wang, Zhong Wang
Summary: Atogepant has demonstrated good efficacy and safety in the prophylactic treatment of migraine, effectively reducing monthly migraine days, headache days, and medication use days, while increasing the proportion of patients with >= 50% reduction in monthly migraine days.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Messoud Ashina, Peter McAllister, Roger Cady, Joe Hirman, Anders Ettrup
Summary: This subgroup analysis evaluated the efficacy and safety of eptinezumab for migraine prevention in patients with self-reported aura. The results showed that eptinezumab had comparable preventive efficacy for both episodic and chronic migraine patients with aura, with a similarly favorable safety and tolerability profile as the overall study populations.
Article
Clinical Neurology
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Michail Vikelis
Summary: The efficacy and safety of fremanezumab for migraine prophylaxis in patients with previous treatment failure were assessed. The study showed that fremanezumab significantly reduced headache days and improved quality of life in patients with high-frequency episodic migraines and chronic migraines. Mild adverse events were reported.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow, Christian Lampl
Summary: This study evaluated the efficacy, safety, and tolerability of fremanezumab in patients aged >= 60 years with migraine, showing significant reductions in monthly migraine days over 12 weeks and improvements in quality of life, with low rates of adverse events.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
Jack D. Schim, Carlton Anderson, Elizabeth Brunner, Joe Hirman, Annette Ogbru, Roger Cady, Lora McGill
Summary: This study developed a multivariable model to predict factors affecting the second-dose response to eptinezumab treatment in patients with migraine who initially had a suboptimal response. The results showed that for patients with an unsatisfactory first-dose response, the second dose still had a significant impact on their treatment outcomes, although the response rate was not very high.
Article
Clinical Neurology
Fumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, Koichi Hirata, Sunfa Cheng, Yotaro Numachi, Cheng Peng, Fei Xue, Daniel D. Mikol
Summary: The study evaluated the long-term efficacy, tolerability, and safety of erenumab for preventing episodic migraine in Japanese patients for up to 2 years. Results showed that long-term erenumab treatment demonstrated sustained efficacy for up to 2 years with a safety profile similar to previous studies, supporting its potential as a new therapy for migraine prevention in Japan.
Article
Anesthesiology
Janu Thuraiaiyah, Mohammad Al-Mahdi Al-Karagholi, Fatima Azzahra Elbahi, Zixuan Alice Zhuang, Messoud Ashina
Summary: In a randomized, double-blinded, placebo-controlled, crossover study, researchers found that adenosine does not significantly induce migraine attacks but does cause headache. Adenosine increases heart rate, facial skin blood flow, and superficial temporal artery diameter, while decreasing middle cerebral artery blood flow.
Article
Clinical Neurology
Messoud Ashina, Stewart J. Tepper, Uwe Reuter, Andrew M. Blumenfeld, Susan Hutchinson, Jing Xia, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman
Summary: This study assessed the long-term safety, tolerability, and efficacy of once-daily oral atogepant 60 mg in adults with migraine. The results showed that daily use of atogepant for preventive treatment of migraine during this 1-year trial was safe, well tolerated, and efficacious.
Review
Clinical Neurology
Lionesa Bahtiri, Andreas Vinther Thomsen, Messoud Ashina, Anders Hougaard
Summary: This systematic review summarizes and evaluates cases of migraine aura-like episodes triggered by sclerotherapy of veins of the lower extremities, and explores possible underlying mechanisms.
Article
Dermatology
Nita Katarina Frifelt Wienholtz, Jacob P. P. Thyssen, Casper Emil Christensen, Simon Francis Thomsen, Katrine Elisabeth Karmisholt, Gregor B. E. Jemec, Hans B. B. Lomholt, Michael Heidenheim, Anne Birgitte Simonsen, Carsten Sand, Christian Vestergaard, Diljit Kaur-Knudsen, Elisabeth Ammitzboll, Erik Lorup, Anne G. G. Danielsen, Gitte Strauss, Lone Skov, Peter H. H. Andersen, Marianne Hald, Luise W. W. Idorn, Messoud Ashina, Claus Zachariae, Alexander Egeberg
Summary: This study validates the Rosacea Area and Severity Index (RASI) as an effective tool for evaluating the severity of rosacea, with comparable agreement to the currently used Investigator's Global Assessment (IGA) method. RASI provides a more nuanced evaluation of various rosacea features and the extent of involvement in different facial areas, suggesting its widespread use in clinical and research settings.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Clinical Neurology
Messoud Ashina, Caroline Roos, Lily Qian Li, Mika Komori, David Ayer, Dustin Ruff, John Henry Krege
Summary: During the 12-month extension study, patients treated with lasmiditan showed significant improvements in migraine-related disability and quality of life. No new safety concerns were identified.
Article
Clinical Neurology
Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Andrea Wang, Sunfa Cheng, Jan Klatt, Daniel D. Mikol
Summary: This study evaluated the long-term efficacy and safety of erenumab in patients with chronic migraine. The results showed that long-term treatment with erenumab could consistently reduce monthly migraine days and the efficacy was similar in patients with and without acute medication overuse.
Article
Clinical Neurology
Lili Kokoti, Mohammad Al-Mahdi Al-Karagholi, Cherie Amalie Waldorff Nielsen, Messoud Ashina
Summary: This study investigated the effect of the K-ATP channel blocker glibenclamide on levcromakalim-induced headache in healthy volunteers and found that glibenclamide did not attenuate levcromakalim-induced headache. Future studies should further explore the role of different isoforms of sulfonylurea receptor subunits of K-ATP channels in the pathogenesis of headache and migraine.
Article
Clinical Neurology
Christina Deligianni, Lanfranco Pellesi, Basit Ali Chaudhry, Anne Luise Haulund Vollesen, Agneta Henriette Snoer, Jens Hannibal, Rigmor Hojland Jensen, Messoud Ashina
Summary: In this study, the researchers investigated the effects of PACAP and VIP on plasma levels of VIP and their contribution to induced cluster headache attacks. The results showed a significant increase in plasma VIP levels during PACAP infusion in individuals with episodic cluster headache, but not in those with chronic cluster headache. Further studies are needed to understand the role of VIP and the parasympathetic system in cluster headache.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
William Kristian Karlsson, Hakan Ashina, Christopher Kjaer Cullum, Rune Haeckert Christensen, Haidar Muhsen Al-Khazali, Faisal Mohammad Amin, Messoud Ashina, Afrim Iljazi, Andreas Vinther Thomsen, Basit Ali Chaudhry, Betel Tesfay, Janu Thuraiaiyah, Lili Kokoti, Nadja Bredo Rasmussen, Rogelio Dominguez-Moreno, Thien Phu Do, Zixuan Alice Zhuang
Summary: The REFORM study aims to discover biomarkers that can predict response to erenumab in migraine patients. This article provides a comprehensive description of the study methodology and the baseline characteristics of the study population. Future publications will report the results of the investigations.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Nadja Bredo Rasmussen, Christina Deligianni, Casper Emil Christensen, William Kristian Karlsson, Haidar Muhsen Al-Khazali, Tom Van de Casteele, Charlotte Granhall, Faisal Mohammad Amin, Messoud Ashina
Summary: Lu AG09222, an investigational humanized monoclonal antibody, inhibits PACAP38-induced vasodilation and headache, suggesting its potential as a therapy for PACAP-mediated diseases such as migraine.
JOURNAL OF HEADACHE AND PAIN
(2023)
Review
Clinical Neurology
R. Messina, R. H. Christensen, I. Cetta, M. Ashina, M. Filippi
Summary: This systematic review provides a comprehensive overview of the mechanisms of actions of headache treatments and potential biomarkers of treatment response revealed by neuroimaging studies. The findings suggest that acupuncture, neuromodulation, and medication withdrawal therapies can improve headache by altering headache-affected brain areas. However, there is currently no clear evidence for the specific location of action for each treatment and no reliable imaging predictors of efficacy.
JOURNAL OF HEADACHE AND PAIN
(2023)
Correction
Clinical Neurology
Faisal Mohammad Amin, Roberto De Icco, Mohammad Al-Mahdi Al-Karagholi, Jayachandra M. Raghava, Frauke Wolfram, Henrik B. W. Larsson, Messoud Ashina
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Thien Phu Do, Mikala Domgaard, Simon Stefansen, Timothy J. Steiner, Messoud Ashina
Summary: This study aims to characterize healthcare utilization patterns of headache patients in Denmark. The results showed that a quarter of patients who were able to manage their headaches had never consulted a doctor. Additionally, some patients used opioids for headache treatment. Therefore, there is a need for increased public education and awareness, as well as policy adjustments to better address the burden of headache diseases on the population's health.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Messoud Ashina, Richard B. Lipton, Jessica Ailani, Jan Versijpt, Simona Sacco, Dimos D. Mitsikostas, Cecilie Laurberg Christoffersen, Bjorn Sperling, Anders Ettrup
Summary: This post hoc analysis suggests that eptinezumab can reduce monthly migraine days in patients with difficult-to-treat migraines. The majority of patients who responded to eptinezumab during the initial weeks maintained or improved their response during the later weeks. Additionally, a significant number of initial non-responders showed a response after the second infusion.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Messoud Ashina, Dimos D. Mitsikostas, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Hans-Christoph Diener
Summary: This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial. The results showed that the NNT, NNH, and LHH for quarterly and monthly fremanezumab compare favorably with those for traditional oral preventive medications, including topiramate, valproate, and propranolol.